Danielle Gerhard, PhD | Mar 22, 2024 | 10+ min read
With the help of directed evolution, scientists inch closer to developing viral vectors that can cross the human blood-brain barrier to deliver gene therapy.
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
A reference sequence for this emerging model organism will facilitate research on type 2 diabetes and the health effects of circadian rhythm disruption.
The Sloan Kettering researcher used mutagenic screening to probe genes and molecular pathways, including Toll and Hedgehog, essential to development in fruit flies and mice.
Clinical trials that target human endogenous retroviruses to treat multiple sclerosis, ALS, and other ailments are underway, but many questions remain about how these sequences may disrupt our biology.